Health Care Supplies

BLUE SAIL MEDICAL

BLUE SAIL MEDICAL released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 1.625 B, actual EPS CNY 0

BLUE SAIL MEDICAL released FY2025 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 5.74 B, actual EPS CNY -0.76

BLUE SAIL MEDICAL released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 1.558 B, actual EPS CNY -0.5082

BLUE SAIL MEDICAL to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

BLUE SAIL MEDICAL FY2025 Earnings Release on April 29, 2026 After-Market BJT

BLUE SAIL MEDICAL released FY2025 Q3 earnings on October 30 Pre-Market BJT, actual revenue CNY 1.401 B, actual EPS CNY -0.1526

BLUE SAIL MEDICAL released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 4.182 B, actual EPS CNY -0.2633

BLUE SAIL MEDICAL to Release FY2025 Q3 Earnings on October 31, Pre-Market BJT

BLUE SAIL MEDICAL released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 2.781 B, actual EPS CNY -0.13

BLUE SAIL MEDICAL released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 1.303 B, actual EPS CNY -0.1906

BLUE SAIL MEDICAL to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

BANDAI MedTech Secretary Interprets Impact of Medical Insurance Policy Adjustments

Luohan Medical Expected Net Loss of 150-100 Million Yuan in First Half of 2025

Blue Sail Medical Secretary Responds to Acquisition of Steam Company Inquiry

Blue Sail Medical's Cardiovascular Product Obtains EU CE Certification

BLUE SAIL MEDICAL released FY2024 Q4 earnings on April 28 After-Market BJT, actual revenue CNY 1.599 B, actual EPS CNY -0.2143

BLUE SAIL MEDICAL released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 1.478 B, actual EPS CNY 0.08

BLUE SAIL MEDICAL released FY2024 annual earnings on April 28 After-Market BJT, actual revenue CNY 6.253 B, actual EPS CNY -0.44

BLUE SAIL MEDICAL to Release FY2025 Q1 Earnings on April 29 After-Market BJT

BLUE SAIL MEDICAL FY2024 Earnings Release Scheduled for April 29, 2025 After-Market BJT

159546

002382

562820

588200

159516

159558

002487

561980

159995

688082

Since March, nearly 350 listed companies have accepted institutional research, covering popular sectors such as semiconductors, new energy, and information technology. Among them, 10 companies received over a hundred institutional visits, including DHI, BLUE SAIL MEDICAL, and ACMSH, becoming key targets of institutional attention

Wallstreetcn

Guotai CSI All Share Integrated Circuit ETF

Harvest CSI All Share Integrated Circuit ETF

Harvest SSE STAR Chip ETF

Guotai CSI Semiconductor Material Equipment Theme ETF

E Fund CSI Semiconductor Material & Equipment Thematic ETF

China Merchants CSI Semiconductor Industry ETF

ChinaAMC Guozheng Semiconductor Chip ETF

ACMSH

Nearly 350 Listed Companies Received Institutional Research in March, with Semiconductors and New Energy Among Favored Sectors

301122

300453

300677

300981

002950

A-share medical consumables stocks continue to rise, ZHYL and INTCO are approaching a 20% limit-up, Allmed Medical and BLUE SAIL MEDICAL previously hit the limit-up, Sanxin Medtec and CAINA have leading gains

CAINA

Sanxin Medtec

INTCO

ZHYL

Allmed Medical

According to the Zhitong Finance APP, BLUE SAIL MEDICAL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 4.182 billion yuan, a year-on-year decrease of 10.15%. The net loss attributable to shareholders of the listed company was 286 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 364 million yuan. The basic loss per share was 0.28 yuan

Zhitong

BLUE SAIL MEDICAL released its performance for the first three quarters, with a net loss attributable to the parent company of 286 million yuan

According to the Zhitong Finance APP, BLUE SAIL MEDICAL released its semi-annual report for 2025, showing an operating income of 2.781 billion yuan, a year-on-year decrease of 7.49%. The net loss attributable to shareholders of the listed company was 135 million yuan, a year-on-year narrowing of 15.88%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 210 million yuan, a year-on-year increase of 11.82%. The basic loss per share was 0.13 yuan

BLUE SAIL MEDICAL released its performance for the first half of the year, with a net loss attributable to the parent company of 135 million yuan, narrowing by 15.88%

601916

02016

BLUE SAIL MEDICAL announced that its subsidiary Shandong Blue Sail New Materials applied for a credit line of no more than 100 million from CZBANK, with good progress on the guarantee. In 2024, the company and its subsidiaries plan to apply for a comprehensive credit line of no more than 1.71 billion. The subsidiary's debt-to-asset ratio is 63.12%, and after the new guarantee, the guarantee balance is 385 million, with a remaining available limit of 949 million. The financial performance of the guaranteed party is poor, but there are no adverse guarantee situations

CZBANK

BLUE SAIL MEDICAL: Subsidiary obtains credit line of 100 million, disclosure of guarantee progress and situation

BLUE SAIL MEDICAL announced that it is expected to trigger the condition for the downward adjustment of the conversion price of "BLUE SAIL Convertible Bonds." As of July 21, 2025, the company's stock has closed below the conversion price of RMB 12.00 per share for 85% of the 10 trading days. If triggered, the company will convene a board meeting to review whether to make the adjustment and will disclose the information in a timely manner. The current conversion period is from December 3, 2020, to May 27, 2026, and the latest conversion price was adjusted to RMB 12.00 per share on July 8, 2025

BLUE SAIL MEDICAL expects to trigger the condition for the downward adjustment of the conversion price of "BLUE SAIL Convertible Bonds"

According to the Zhitong Finance APP, BLUE SAIL MEDICAL announced that its subsidiary, NVTGmbH in the cardiovascular division, has developed a new generation of recyclable transcatheter aortic valve replacement (TAVR) delivery system IMPERIA™ (referred to as "IMPERIA™ delivery system"), which has obtained CE certification from the European Union. This delivery system is used in conjunction with the company's already listed ALLEGRA™ series aortic valves to achieve recyclable functionality

BLUE SAIL MEDICAL's subsidiary's next-generation recyclable transcatheter aortic valve replacement delivery system has obtained CE certification

Blue Sail Medical announced that its information disclosure obligor, Blue Sail Group, has been diluted from 98% to 47.0013% in its equity stake in Blue Sail Investment due to an increase in capital from Shandong Langhui to Blue Sail Investment. As a result, the indirect controlling shareholder of Blue Sail Medical has changed from Blue Sail Group to Shandong Langhui. The shareholding ratio of Blue Sail Group in Blue Sail Medical has decreased from 23.31% to 10.96%. This equity change does not involve the buying or selling of shares, and Blue Sail Group has no plans to increase or decrease its holdings in the next 12 months

BLUE SAIL MEDICAL: The shareholding ratio of Blue Sail Group has decreased to 10.96%

According to the announcement from Dolphin Research, BLUE SAIL MEDICAL has stated that in order to broaden financing channels and optimize the company's debt structure, and in consideration of the company's actual situation, it agrees to privately issue corporate bonds not exceeding RMB 500 million (including RMB 500 million) to professional investors. The funds raised from this bond issuance are intended to be used for the company's production and operational needs, repayment of interest-bearing debts, replenishment of working capital, and (or) project investments, equity investments, and other business activities that comply with national laws, regulations, and policy requirements

BLUE SAIL MEDICAL plans to issue no more than 500 million yuan in private placement corporate bonds

According to the Zhitong Finance APP, BLUE SAIL MEDICAL has released its annual performance forecast for 2024, expecting a net loss attributable to the parent company of between 370 million yuan and 470 million yuan for the year. During the reporting period, the sales revenue of the cardiovascular and cerebrovascular division exceeded 1.1 billion yuan, a year-on-year increase of approximately 12%. The gross profit margin further improved, continuing the positive trend of annual revenue growth, decreasing sales expense ratio and management expense ratio, and a significant narrowing of operating losses since the national procurement of coronary stents in 2021

BLUE SAIL MEDICAL issues a profit warning, expecting a net loss of 370 million to 470 million yuan for the fiscal year 2024

BLUE SAIL MEDICAL(002382.SZ)